Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.
Local restrictions - provision of cross-border services
Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.
This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.
By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.
Year after year, things are becoming quite similar for Straumann. In this case, that’s a very good thing. After tripling its profits in 2016, up to 230 million Swiss francs compared to 72 million in 2015, the global leader in dental implants, with a 23% market share in 2016, is having an excellent 2017.
Over the first nine months, its revenue was up 18.7%, even though the industry was only expected to grow by 3% or 4% in 2017. “Straumann is one of the most profitable companies in the medical industry, with a margin close to 20%,” said Jérôme Schupp, independent analyst. “On the stock market, it is one of Switzerland’s biggest successes.” Over the last five years, its share price increased seven-fold.
To what does Straumann owe its success? The Basel-based company that manufactures teeth replacement solutions is better positioned than its competition. Its offerings include both premium and more affordable products, making it possible to bring in revenue from all over the world. “Straumann is also highly innovative in order to stay on the cutting edge of new technologies,” said Schupp. “That’s important because even though it may seem insignificant, the dental replacement sector is actually a rather technical industry.”
The company recently launched new products, notably the Bone Level Tapered (BLT) implants. Furthermore, when a potential competitor develops a new procedure, the Swiss company doesn’t hesitate to get involved. In June 2017, Straumann took a 35% stake in Rapid Shape, a German manufacturer of 3D implants for the dental market.